Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.

Jia H, Wang Y, Morris CD, Jacques V, Gottesfeld JM, Rusche JR, Thomas EA.

PLoS One. 2016 Mar 31;11(3):e0152498. doi: 10.1371/journal.pone.0152498. eCollection 2016.

2.

Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW.

Blood. 2015 Nov 19;126(21):2392-403. doi: 10.1182/blood-2015-03-632984. Epub 2015 Oct 7.

3.

Histone Deacetylase Inhibition via RGFP966 Releases the Brakes on Sensory Cortical Plasticity and the Specificity of Memory Formation.

Bieszczad KM, Bechay K, Rusche JR, Jacques V, Kudugunti S, Miao W, Weinberger NM, McGaugh JL, Wood MA.

J Neurosci. 2015 Sep 23;35(38):13124-32. doi: 10.1523/JNEUROSCI.0914-15.2015.

4.

Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia.

Soragni E, Chou CJ, Rusche JR, Gottesfeld JM.

Front Neurol. 2015 Mar 5;6:44. doi: 10.3389/fneur.2015.00044. eCollection 2015.

5.

Epigenetic therapy for Friedreich ataxia.

Soragni E, Miao W, Iudicello M, Jacoby D, De Mercanti S, Clerico M, Longo F, Piga A, Ku S, Campau E, Du J, Penalver P, Rai M, Madara JC, Nazor K, O'Connor M, Maximov A, Loring JF, Pandolfo M, Durelli L, Gottesfeld JM, Rusche JR.

Ann Neurol. 2014 Oct;76(4):489-508. doi: 10.1002/ana.24260. Epub 2014 Sep 16.

6.
7.

Histone deacetylases 1 and 2 maintain S-phase chromatin and DNA replication fork progression.

Bhaskara S, Jacques V, Rusche JR, Olson EN, Cairns BR, Chandrasekharan MB.

Epigenetics Chromatin. 2013 Aug 15;6(1):27. doi: 10.1186/1756-8935-6-27.

8.

Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia.

Gottesfeld JM, Rusche JR, Pandolfo M.

J Neurochem. 2013 Aug;126 Suppl 1:147-54. doi: 10.1111/jnc.12302. Review.

9.

The DcpS inhibitor RG3039 improves motor function in SMA mice.

Van Meerbeke JP, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin MY, Rucki AA, Wee CD, Xia B, Sharma S, Jacques V, Li DK, Pellizzoni L, Rusche JR, Ko CP, Sumner CJ.

Hum Mol Genet. 2013 Oct 15;22(20):4074-83. doi: 10.1093/hmg/ddt257. Epub 2013 May 31.

10.

Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia.

Plasterer HL, Deutsch EC, Belmonte M, Egan E, Lynch DR, Rusche JR.

PLoS One. 2013 May 17;8(5):e63958. doi: 10.1371/journal.pone.0063958. Print 2013.

11.

HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner.

Malvaez M, McQuown SC, Rogge GA, Astarabadi M, Jacques V, Carreiro S, Rusche JR, Wood MA.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52. doi: 10.1073/pnas.1213364110. Epub 2013 Jan 7.

12.

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM.

Parkinsonism Relat Disord. 2013 Feb;19(2):260-4. doi: 10.1016/j.parkreldis.2012.07.001. Epub 2012 Aug 14.

PMID:
22901956
13.

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.

Soragni E, Xu C, Plasterer HL, Jacques V, Rusche JR, Gottesfeld JM.

J Child Neurol. 2012 Sep;27(9):1164-73. doi: 10.1177/0883073812448533. Epub 2012 Jul 4. Review.

14.

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.

Neurobiol Dis. 2012 May;46(2):351-61.

15.

A gene expression phenotype in lymphocytes from Friedreich ataxia patients.

Coppola G, Burnett R, Perlman S, Versano R, Gao F, Plasterer H, Rai M, Saccá F, Filla A, Lynch DR, Rusche JR, Gottesfeld JM, Pandolfo M, Geschwind DH.

Ann Neurol. 2011 Nov;70(5):790-804. doi: 10.1002/ana.22526.

16.

Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route.

Xu C, Soragni E, Jacques V, Rusche JR, Gottesfeld JM.

Pharmaceuticals (Basel). 2011 Dec 14;4(12):1578-1590.

17.

Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.

Soragni E, Xu C, Cooper A, Plasterer HL, Rusche JR, Gottesfeld JM.

Methods Mol Biol. 2011;793:495-508. doi: 10.1007/978-1-61779-328-8_32.

18.

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model.

Sandi C, Pinto RM, Al-Mahdawi S, Ezzatizadeh V, Barnes G, Jones S, Rusche JR, Gottesfeld JM, Pook MA.

Neurobiol Dis. 2011 Jun;42(3):496-505. doi: 10.1016/j.nbd.2011.02.016. Epub 2011 Mar 17.

19.

HDAC3 is a critical negative regulator of long-term memory formation.

McQuown SC, Barrett RM, Matheos DP, Post RJ, Rogge GA, Alenghat T, Mullican SE, Jones S, Rusche JR, Lazar MA, Wood MA.

J Neurosci. 2011 Jan 12;31(2):764-74. doi: 10.1523/JNEUROSCI.5052-10.2011.

20.

Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.

Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR, Gottesfeld JM, Pandolfo M.

PLoS One. 2010 Jan 21;5(1):e8825. doi: 10.1371/journal.pone.0008825.

21.

Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.

Xu C, Soragni E, Chou CJ, Herman D, Plasterer HL, Rusche JR, Gottesfeld JM.

Chem Biol. 2009 Sep 25;16(9):980-9. doi: 10.1016/j.chembiol.2009.07.010.

22.

CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.

Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ.

Neurology. 2008 Sep 16;71(12):917-24. doi: 10.1212/01.wnl.0000325915.00112.61.

PMID:
18794494
23.

Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients.

Jensen JE, Daniels M, Haws C, Bolo NR, Lyoo IK, Yoon SJ, Cohen BM, Stoll AL, Rusche JR, Renshaw PF.

Exp Clin Psychopharmacol. 2008 Jun;16(3):199-206. doi: 10.1037/1064-1297.16.3.199.

PMID:
18540779
24.

Increased amygdala fMRI activation after secretin administration.

Yurgelun-Todd DA, Rogowska J, Gruber SA, Bogorodzki P, Simpson NS, Irvin RW, Jauregui KA, Strong RA, Rusche JR.

Exp Clin Psychopharmacol. 2008 Jun;16(3):191-8. doi: 10.1037/1064-1297.16.3.191.

PMID:
18540778
25.

Effects of uridine on kindling.

Zhao Q, Shatskikh T, Marolewski A, Rusche JR, Holmes GL.

Epilepsy Behav. 2008 Jul;13(1):47-51. doi: 10.1016/j.yebeh.2008.02.002. Epub 2008 Mar 5.

PMID:
18321784
26.

Lack of effect of secretin on kindling and seizures.

Zhao Q, Boismenu R, Rusche JR, Holmes GL.

Epilepsy Behav. 2006 Aug;9(1):46-50. Epub 2006 May 24.

PMID:
16723277
27.

Effects of uridine in models of epileptogenesis and seizures.

Zhao Q, Marolewski A, Rusche JR, Holmes GL.

Epilepsy Res. 2006 Jul;70(1):73-82. Epub 2006 Apr 18.

PMID:
16621451
28.

A secretin i.v. infusion activates gene expression in the central amygdala of rats.

Goulet M, Shiromani PJ, Ware CM, Strong RA, Boismenu R, Rusche JR.

Neuroscience. 2003;118(4):881-8.

PMID:
12732234
29.

Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse.

Banks WA, Goulet M, Rusche JR, Niehoff ML, Boismenu R.

J Pharmacol Exp Ther. 2002 Sep;302(3):1062-9.

30.

Unique Structures Generated by Ugi 3CC Reactions Using Bifunctional Starting Materials Containing Aldehyde and Carboxylic Acid.

Zhang J, Jacobson A, Rusche JR, Herlihy W.

J Org Chem. 1999 Feb 5;64(3):1074-1076. No abstract available.

PMID:
11674195
31.

CTLA4Ig-induced linked regulation of allogeneic T cell responses.

Lee RS, Rusche JR, Maloney ME, Sachs DH, Sayegh MH, Madsen JC.

Transplant Proc. 2001 Feb-Mar;33(1-2):88-9. No abstract available.

PMID:
11266718
32.

CTLA4Ig and donor-specific transfusion prolongs cardiac allograft survival in the miniature swine.

Lee RS, Rusche JR, Cheatham LA, Yamada K, Houser SL, Maloney ME, Amoah HC, Mezrich JB, Sayegh MH, Madsen JC.

J Heart Lung Transplant. 2001 Feb;20(2):150. No abstract available.

PMID:
11250209
33.

CTLA4Ig-induced linked regulation of allogeneic T cell responses.

Lee RS, Rusche JR, Maloney ME, Sachs DH, Sayegh MH, Madsen JC.

J Immunol. 2001 Feb 1;166(3):1572-82.

34.

Schwann cell heparan sulfate proteoglycans play a critical role in glial growth factor/neuregulin signaling.

Sudhalter J, Whitehouse L, Rusche JR, Marchionni MA, Mahanthappa NK.

Glia. 1996 May;17(1):28-38.

PMID:
8723840
35.

The amino terminal domain of HIV-1 Rev is required for discrimination of the RRE from nonspecific RNA.

Daly TJ, Doten RC, Rusche JR, Auer M.

J Mol Biol. 1995 Oct 20;253(2):243-58.

PMID:
7563086
36.

Differences in the binding of blocking anti-CD11b monoclonal antibodies to the A-domain of CD11b.

Violette SM, Rusche JR, Purdy SR, Boyd JG, Cos J, Silver S.

J Immunol. 1995 Sep 15;155(6):3092-101.

PMID:
7673724
37.

Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats.

Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR.

Stroke. 1994 Apr;25(4):869-75; discussion 875-6.

PMID:
8160235
38.

Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat.

Chen H, Chopp M, Zhang RL, Bodzin G, Chen Q, Rusche JR, Todd RF 3rd.

Ann Neurol. 1994 Apr;35(4):458-63.

PMID:
8154873
39.

Molecular determinants of lipid mediator-induced leukocyte adherence and emigration in rat mesenteric venules.

Zimmerman BJ, Holt JW, Paulson JC, Anderson DC, Miyasaka M, Tamatani T, Todd RF 3rd, Rusche JR, Granger DN.

Am J Physiol. 1994 Mar;266(3 Pt 2):H847-53.

PMID:
8160832
40.

Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage.

Kurose I, Anderson DC, Miyasaka M, Tamatani T, Paulson JC, Todd RF, Rusche JR, Granger DN.

Circ Res. 1994 Feb;74(2):336-43.

PMID:
7507416
41.

Biochemical characterization of binding of multiple HIV-1 Rev monomeric proteins to the Rev responsive element.

Daly TJ, Doten RC, Rennert P, Auer M, Jaksche H, Donner A, Fisk G, Rusche JR.

Biochemistry. 1993 Oct 5;32(39):10497-505.

PMID:
8399195
42.

Perturbation of the carboxy terminus of HIV-1 Rev affects multimerization on the Rev responsive element.

Daly TJ, Rennert P, Lynch P, Barry JK, Dundas M, Rusche JR, Doten RC, Auer M, Farrington GK.

Biochemistry. 1993 Aug 31;32(34):8945-54.

PMID:
8364040
43.

Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.

White-Scharf ME, Potts BJ, Smith LM, Sokolowski KA, Rusche JR, Silver S.

Virology. 1993 Jan;192(1):197-206.

PMID:
7685962
44.

In vitro inhibition of a variety of human immunodeficiency virus isolates by a broadly reactive, V3-directed heteroconjugate antibody.

Higgins PJ, Paradis T, Potts BJ, White-Scharf ME, Rusche JR, Scott CF.

J Infect Dis. 1992 Jul;166(1):198-202.

PMID:
1607697
45.
46.

Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate.

Cook KS, Fisk GJ, Hauber J, Usman N, Daly TJ, Rusche JR.

Nucleic Acids Res. 1991 Apr 11;19(7):1577-83.

47.
48.

Circular dichroism studies of the HIV-1 Rev protein and its specific RNA binding site.

Daly TJ, Rusche JR, Maione TE, Frankel AD.

Biochemistry. 1990 Oct 23;29(42):9791-5.

PMID:
2125482
49.

C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.

Devash Y, Matthews TJ, Drummond JE, Javaherian K, Waters DJ, Arthur LO, Blattner WA, Rusche JR.

AIDS Res Hum Retroviruses. 1990 Mar;6(3):307-16.

PMID:
2340200
50.

HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence.

Malim MH, Tiley LS, McCarn DF, Rusche JR, Hauber J, Cullen BR.

Cell. 1990 Feb 23;60(4):675-83.

PMID:
2406030

Supplemental Content

Loading ...
Support Center